ArticleACS chemical biology2016
Host Cell Interactions Are a Significant Barrier to the Clinical Utility of Peptide Antibiotics.
Article in ACS chemical biology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 49 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
49 citing papers in PubMed, 88 citations in OpenAlex.
- Antimicrobial peptides in anti-infective and immunomodulatory applications: Mechanisms, challenges, and emerging computational design.Zoological research · 2026Review
- Peptide-based drug design using generative AI.Chemical communications (Cambridge, England) · 2026Review
- Marine Antimicrobial Peptides: Advances in Discovery, Multifunctional Mechanisms, and Therapeutic Translation Challenges.Marine drugs · 2025Review
- Antimicrobial Peptides Can Facilitate Whole Blood Safety from Bacteria: A Proof of Concept.ACS infectious diseases · 2025Article
- Cyclization increases bactericidal activity of arginine-rich cationic cell-penetrating peptide forMicrobiology spectrum · 2024Article
- Molecular Mechanisms of Bacterial Resistance to Antimicrobial Peptides in the Modern Era: An Updated Review.Microorganisms · 2024Review
- Development of a Selective and Stable Antimicrobial Peptide.ACS infectious diseases · 2024Article
- Pharmacokinetics and pharmacodynamics of antibacterial peptide NZX in Staphylococcus aureus mastitis mouse model.Applied microbiology and biotechnology · 2024Article
- Characterization of a New Immunosuppressive and Antimicrobial Peptide, DRS-DA2, Isolated from the Mexican Frog,International journal of inflammation · 2024Article
- Modeling selectivity of antimicrobial peptides: how it depends on the presence of host cells and cell density.RSC advances · 2023Article
- Rapid Assessment of Susceptibility of Bacteria and Erythrocytes to Antimicrobial Peptides by Single-Cell Impedance Cytometry.ACS sensors · 2023Article
- Optimization of Host Cell-Compatible, Antimicrobial Peptides Effective against Biofilms and Clinical Isolates of Drug-Resistant Bacteria.ACS infectious diseases · 2023Article
- The Remarkable Innate Resistance of Burkholderia bacteria to Cationic Antimicrobial Peptides: Insights into the Mechanism of AMP Resistance.The Journal of membrane biology · 2022Article
- Novel Diagnostic Technologies and Therapeutic Approaches Targeting Chronic Wound Biofilms and Microbiota.Current dermatology reports · 2022Article
- Integrated Design of a Membrane-Lytic Peptide-Based Intravenous Nanotherapeutic Suppresses Triple-Negative Breast Cancer.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2022Article
- Bacteriophage-encoded lethal membrane disruptors: Advances in understanding and potential applications.Frontiers in microbiology · 2022Review
- Local rigidification and possible coacervation of the Escherichia coli DNA by cationic nylon-3 polymers.Biophysical journal · 2021Article
- Host Defense Peptides: Dual Antimicrobial and Immunomodulatory Action.International journal of molecular sciences · 2021Review
- Membrane-selective nanoscale pores in liposomes by a synthetically evolved peptide: implications for triggered release.Nanoscale · 2021Article
- Unexpected Enhancement of Antimicrobial Polymer Activity againstMolecules (Basel, Switzerland) · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
Despite longstanding promise and many known examples, antimicrobial peptides (AMPs) have failed, thus far, to impact human medicine. On the basis of the physical chemistry and mechanism of action of AMPs, we hypothesized that host cell interactions could contribute to a loss of activity in vivo where host cells are highly concentrated. To test this idea, we characterized AMP activity in the presence of human red blood cells (RBC). Indeed, we show that most of a representative set of natural and synthetic AMPs tested are significantly inhibited by preincubation with host cells and would be effectively inactive at physiological cell density. We studied an example broad-spectrum AMP, ARVA (RRGWALRLVLAY), in a direct, label-free binding assay. We show that weak binding to host cells, coupled with their high concentration, is sufficient to account for a loss of useful activity, for at least some AMPs, because >1 × 10
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.